Real World Trial of Inhaled Insulin for Type 2 Diabetes Management
Author Information
Author(s): Nick Freemantle, Thomas Strack
Primary Institution: University of Birmingham
Hypothesis
Will availability of inhaled human insulin (Exubera®) improve management of type 2 diabetes?
Conclusion
The study suggests that the availability of inhaled insulin may improve patient acceptance of insulin therapy and glycemic control.
Supporting Evidence
- Patients were three times more likely to choose insulin therapy when inhaled insulin was available.
- More than 85% of subjects chose to remain on inhaled insulin after initial treatment.
- Inhaled insulin was preferred over subcutaneous insulin or oral agents when offered as an option.
Takeaway
This study is trying to find out if using inhaled insulin can help people with diabetes feel better about using insulin and control their blood sugar more effectively.
Methodology
The study is a 52-week, open label, randomized, parallel, multicenter trial with approximately 700 patients with type 2 diabetes poorly controlled by oral agents.
Potential Biases
Potential biases may arise from the open-label design and the voluntary nature of treatment choice.
Limitations
The study design may not fully capture the long-term health benefits and pharmacoeconomic impact of inhaled insulin.
Participant Demographics
Approximately 700 patients aged 35 to 80 years with type 2 diabetes poorly controlled despite treatment with two or more oral agents.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI: 2.93 to 5.95
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website